Lu W, Andrieu J M
Laboratory of Molecular Oncology and Virology, Necker Faculty of Medicine at Saints-Pères Biomedical Center, René Descartes University, Paris, France.
J Virol. 2001 Oct;75(19):8949-56. doi: 10.1128/JVI.75.19.8949-8956.2001.
Despite significant immune recovery with potent highly active antiretroviral therapy (HAART), eradication of human immunodeficiency virus (HIV) from the bodies of infected individuals represents a challenge. We hypothesized that an inadequate or inappropriate signal in virus-specific antigen presentation might contribute to the persistent failure to mount efficient anti-HIV immunity in most HIV-infected individuals. Here, we conducted an in vitro study with untreated (n = 10) and HAART-treated (n = 20) HIV type 1 (HIV-1) patients which showed that pulsing of monocyte-derived dendritic cells (DC) with aldrithiol-2-inactivated autologous virus resulted in the expansion of virus-specific CD8(+) T cells which were capable of killing HIV-1-infected cells and eradicating the virus from cultured patient peripheral blood mononuclear cells independently of the disease stages and HAART response statuses of the patients. This in vitro anti-HIV effect was further enhanced by the HIV protease inhibitor indinavir (at a nonantiviral concentration), which has been shown previously to be able to up-regulate directly patient T-cell proliferation following immune stimulation. However, following a 2-day treatment with culture supernatant derived from immune-activated T cells (which mimics an in vivo environment of HIV-disseminated and immune-activated lymphoid tissues), DC lost their capacity to present de novo inactivated-virus-derived antigens. These findings provide important information for understanding the establishment of chronic HIV infection and indicate a perspective for clinical use of DC-based therapeutic vaccines against HIV.
尽管高效抗逆转录病毒疗法(HAART)能使免疫显著恢复,但要从受感染个体体内清除人类免疫缺陷病毒(HIV)仍面临挑战。我们推测,病毒特异性抗原呈递中信号不足或不适当可能是多数HIV感染个体持续无法产生有效抗HIV免疫力的原因。在此,我们对未经治疗的(n = 10)和接受HAART治疗的(n = 20)1型HIV(HIV-1)患者进行了一项体外研究,结果显示,用醛硫醇-2灭活的自体病毒刺激单核细胞衍生的树突状细胞(DC),可导致病毒特异性CD8(+) T细胞扩增,这些细胞能够杀死HIV-1感染细胞,并独立于患者的疾病阶段和HAART反应状态从培养的患者外周血单核细胞中清除病毒。HIV蛋白酶抑制剂茚地那韦(在非抗病毒浓度下)可进一步增强这种体外抗HIV效应,此前已证明该抑制剂在免疫刺激后能够直接上调患者T细胞增殖。然而,用免疫激活T细胞的培养上清液处理2天(模拟HIV传播和免疫激活的淋巴组织的体内环境)后,DC失去了重新呈递灭活病毒衍生抗原的能力。这些发现为理解慢性HIV感染的建立提供了重要信息,并为基于DC的抗HIV治疗性疫苗的临床应用指明了方向。